In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

Published Date: 20 May 2024

A 42% lower risk of tumor death, progression, or recurrence is demonstrated by the CheckMate 77T trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

2.

Is There a Role for Stimulants in Beating Cancer Fatigue?

3.

Gene therapy for glioblastoma is effectively created by researchers.

4.

What Do Patients Want Doctors to Know About Breast Cancer Recurrence?

5.

Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot